Royce & Associates LP Has $3.39 Million Position in Accuray Incorporated (NASDAQ:ARAY)

Royce & Associates LP decreased its position in shares of Accuray Incorporated (NASDAQ:ARAY) by 34.7% during the 3rd quarter, Holdings Channel reports. The institutional investor owned 1,882,369 shares of the medical equipment provider’s stock after selling 1,000,167 shares during the quarter. Royce & Associates LP’s holdings in Accuray were worth $3,388,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of ARAY. EntryPoint Capital LLC lifted its stake in shares of Accuray by 229.2% during the first quarter. EntryPoint Capital LLC now owns 63,786 shares of the medical equipment provider’s stock valued at $158,000 after acquiring an additional 44,411 shares during the period. Price T Rowe Associates Inc. MD lifted its position in Accuray by 9.9% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 73,146 shares of the medical equipment provider’s stock valued at $181,000 after purchasing an additional 6,583 shares during the period. Williams & Novak LLC boosted its stake in shares of Accuray by 259.2% in the 2nd quarter. Williams & Novak LLC now owns 96,900 shares of the medical equipment provider’s stock valued at $176,000 after purchasing an additional 69,925 shares during the last quarter. Dynamic Advisor Solutions LLC grew its position in shares of Accuray by 81.6% during the 2nd quarter. Dynamic Advisor Solutions LLC now owns 96,900 shares of the medical equipment provider’s stock worth $176,000 after buying an additional 43,550 shares during the period. Finally, Assenagon Asset Management S.A. bought a new stake in shares of Accuray during the second quarter worth approximately $132,000. 64.08% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Separately, StockNews.com cut shares of Accuray from a “buy” rating to a “hold” rating in a research note on Friday.

Accuray Stock Performance

NASDAQ:ARAY opened at $1.70 on Tuesday. The company has a current ratio of 1.63, a quick ratio of 0.87 and a debt-to-equity ratio of 3.59. Accuray Incorporated has a 1-year low of $1.40 and a 1-year high of $3.05. The firm has a market capitalization of $170.97 million, a price-to-earnings ratio of -10.00 and a beta of 1.40. The business’s 50-day moving average price is $1.86 and its two-hundred day moving average price is $1.83.

Accuray (NASDAQ:ARAY) last announced its quarterly earnings results on Wednesday, November 6th. The medical equipment provider reported ($0.04) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.04). The business had revenue of $101.55 million for the quarter, compared to the consensus estimate of $98.10 million. Accuray had a negative net margin of 3.72% and a negative return on equity of 36.93%. During the same period last year, the company posted ($0.03) EPS. On average, equities analysts expect that Accuray Incorporated will post 0.01 earnings per share for the current year.

Accuray Company Profile

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.